Cure51 is a company focused on advancing cancer treatment through the development of a clinical and molecular database. Its primary mission is to create a comprehensive database of cancer survivors, utilizing their unique biological characteristics to identify potential drug targets. By analyzing the biology of long-term cancer survivors, Cure51 aims to aid healthcare researchers in decoding genetic information derived from biopsies, blood tests, imaging, and other samples. This innovative approach seeks to accelerate drug discovery, ultimately contributing to the formulation of new and effective cancer therapies.
IMU Biosciences
Series A in 2024
IMU Biosciences is a company focused on advancing precision medicine through a discovery engine that maps the immune system. It operates an online health diagnostic platform designed to provide medical consultancy services to individuals. The platform offers comprehensive blood test profiles that assess various health markers, including testosterone, ApoA, ApoB, estradiol, glucose, cholesterol, PSA, and iron. By delivering insightful and cost-effective services, IMU Biosciences empowers customers to take control of their health and make informed decisions based on their diagnostic results.
Cromatic
Seed Round in 2023
Cromatic is a software company focused on enhancing the research and development (R&D) processes for life sciences companies by facilitating the outsourcing of scientific tasks. Its innovative platform simplifies the identification and management of outsourcing partners, connecting clients with contract research organizations that provide essential services. By streamlining these processes, Cromatic allows scientists and entrepreneurially-minded professionals in the life sciences sector to concentrate on their core scientific work without the burden of maintaining a physical laboratory. Ultimately, Cromatic aims to improve the efficiency of R&D, enabling its clients to effectively launch and scale their ventures in the biotechnology field.
Hypervision Surgical
Seed Round in 2023
Hypervision Surgical is a company focused on enhancing surgical precision, safety, and efficiency through advanced imaging technology. It has developed a non-contact and non-invasive optical imaging system that utilizes hyperspectral imaging to analyze tissue in real-time. By splitting light into multiple spectral bands, the system enables clinicians to visualize and characterize tissues during surgery without the need for contrast agents, thereby reducing patient risk. This AI-powered solution facilitates advanced computer-assisted tissue analysis, equipping surgeons with critical data that supports informed decision-making during procedures. Hypervision Surgical aims to transform the landscape of surgery by guiding clinicians with innovative imaging solutions that prioritize patient safety and operational effectiveness.
Cortical Labs
Seed Round in 2023
Cortical Labs is a pioneering biological computing startup that aims to transform traditional computing by integrating living neurons into chips. Its innovative biOS creates an interactive reality that transmits data through electrical signals, allowing neuronal activity to influence actions within this environment. This dynamic process enables the neurons to adapt in response to perceived outcomes, enhancing their efficiency and effectiveness. By harnessing the unique capabilities of human neurons, which have evolved over billions of years, Cortical Labs' technology offers a new generation of biological computer chips that provide fluid intelligence and energy efficiency. This advancement opens new possibilities for various sectors, including digital spaces, robotics, science, and personal care, facilitating the development of advanced autonomous systems for future applications.
Onc.AI, Inc. is a technology company founded in 2020 and headquartered in San Carlos, California. It specializes in clinical oncology, utilizing advanced software that integrates genomics, proteomics, and radiomics to enhance oncology diagnostics. By employing deep learning techniques, Onc.AI aims to provide actionable insights that improve treatment outcomes for cancer patients. The company's innovative approach seeks to advance the field of oncology through the development of comprehensive data-driven solutions.
Exer Labs
Series A in 2022
Exer Labs uses AI on mobile and tablet devices as well as computer vision to help fitness users experience a more interactive and affordable at-home workout.